Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Fixed-Dose, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of AR19 (Amphetamine Sulfate) in Adult Subjects (Ages 18-55) With Attention Deficit Hyperactivity Disorder (ADHD)

NCT03659929 is registered in ClinicalTrials.gov with Arbor Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03659929
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03659929 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Fixed-Dose, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of AR19 (Amphetamine Sulfate) in Adult Subjects (Ages 18-55) With Attention Deficit Hyperactivity Disorder (ADHD)
Lead sponsor
Arbor Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
September 18, 2018
Completion date
April 12, 2019
Enrollment
320 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

attention deficit hyperactivity disorder